+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Non-Small Cell Lung Cancer Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033

  • PDF Icon

    Report

  • 175 Pages
  • August 2025
  • Region: Global
  • Acute Market Reports
  • ID: 6167406
Description Jump to:
The global non-small cell lung cancer (NSCLC) market is projected to expand at a CAGR of 10.3% from 2025 to 2033, driven by the rising prevalence of lung cancer, increasing adoption of targeted and immunotherapy drugs, and growing investment in oncology research. NSCLC accounts for approximately 85% of all lung cancer cases worldwide, making it a critical area of focus in oncology drug development. Advancements in biomarker-driven therapies and the availability of personalized treatment regimens are reshaping clinical practices and expanding treatment options.

Increasing Adoption of Targeted and Immunotherapies

Targeted therapies and immunotherapies are transforming the NSCLC treatment landscape. The use of immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, and targeted drugs against EGFR, ALK, and ROS1 mutations have significantly improved patient survival rates. Expanding genetic testing for patients with NSCLC is enabling the adoption of precision medicine, while ongoing clinical trials continue to introduce novel drugs targeting rare mutations. The shift toward combination therapies involving chemotherapy and immunotherapy is also contributing to market growth.

High Cost of Therapies and Access Barriers

Despite the promising outlook, challenges such as the high cost of targeted and immunotherapy treatments and limited access in low- and middle-income regions hinder market penetration. Long treatment durations, adverse side effects, and variability in patient response remain significant barriers. Furthermore, the complexity of drug development and regulatory approval processes adds to the challenges faced by pharmaceutical companies. Nonetheless, increasing government healthcare spending, broader insurance coverage, and ongoing R&D collaborations are expected to ease these constraints.

Market Segmentation by Type

The market is segmented into adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and other types. In 2024, adenocarcinoma accounted for the largest share due to its high prevalence, particularly among non-smokers. Squamous cell carcinoma remains a significant segment, especially in smokers, while large cell carcinoma and other types are less common but require specialized treatment approaches.

Market Segmentation by Treatment

By treatment, the market is divided into chemotherapy, immunotherapy, targeted therapy, and other treatment types. In 2024, immunotherapy dominated the market, driven by approvals of immune checkpoint inhibitors and growing adoption in first-line therapy. Targeted therapy is expanding rapidly with the identification of new biomarkers and rising use of next-generation sequencing. Chemotherapy continues to play a role, particularly in combination regimens, while other treatments include palliative care and supportive interventions.

Regional Insights

In 2024, North America led the NSCLC market, with the U.S. at the forefront due to strong healthcare infrastructure, widespread adoption of biomarker testing, and high access to advanced therapies. Europe followed, supported by robust oncology pipelines and national cancer care strategies in countries like Germany, France, and the UK. Asia Pacific is the fastest-growing region, driven by rising lung cancer prevalence in China, Japan, and India, combined with improving access to innovative drugs. Latin America and Middle East & Africa represent emerging markets where government initiatives and partnerships with pharmaceutical companies are expanding access to oncology treatments.

Competitive Landscape

The 2024 market was dominated by global pharmaceutical leaders investing heavily in oncology R&D. F. Hoffmann-La Roche, AstraZeneca, Merck & Co., Bristol-Myers Squibb, and Novartis led the market with extensive portfolios in targeted therapy and immuno-oncology. Pfizer, Eli Lilly, and Janssen Biotech maintained significant presence in chemotherapy and targeted treatment options. Sanofi, Takeda, and AbbVie expanded their pipelines through collaborations and acquisitions. Astellas Pharma, Merus, Sun Pharmaceutical, and Xcovery contributed with specialized or regionally focused oncology solutions. Competitive differentiation is shaped by drug efficacy, safety, biomarker targeting, pipeline innovation, and global distribution reach.

Historical & Forecast Period

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Non-Small Cell Lung Cancer market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users & consumption volume, price, and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Non-Small Cell Lung Cancer market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

  • Type
  • Adenocarcinoma
  • Squamous cell carcinoma
  • Large cell carcinoma
  • Other types
  • Treatment
  • Chemotherapy
  • Immunotherapy
  • Targeted therapy
  • Other treatment types
  • Gender
  • Male
  • Female
  • End Use
  • Hospitals
  • Specialty clinics
  • Other end use

Region Segment (2023 - 2033; US$ Million)

  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Non-Small Cell Lung Cancer market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Non-Small Cell Lung Cancer market?
  • Which is the largest regional market for Non-Small Cell Lung Cancer market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Non-Small Cell Lung Cancer market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Non-Small Cell Lung Cancer market worldwide?

This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Non-Small Cell Lung Cancer Market
2.2. Global Non-Small Cell Lung Cancer Market, By Type, 2024 (US$ Million)
2.3. Global Non-Small Cell Lung Cancer Market, By Treatment, 2024 (US$ Million)
2.4. Global Non-Small Cell Lung Cancer Market, By Gender, 2024 (US$ Million)
2.5. Global Non-Small Cell Lung Cancer Market, By End Use, 2024 (US$ Million)
2.6. Global Non-Small Cell Lung Cancer Market, By Geography, 2024 (US$ Million)
2.7. Attractive Investment Proposition by Geography, 2024
3. Non-Small Cell Lung Cancer Market: Competitive Analysis
3.1. Market Positioning of Key Non-Small Cell Lung Cancer Market Vendors
3.2. Strategies Adopted by Non-Small Cell Lung Cancer Market Vendors
4. Non-Small Cell Lung Cancer Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Non-Small Cell Lung Cancer Market Value, 2023 - 2033, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Technology Landscape
4.6.4. Legal Landscape
4.6.5. Social Landscape
5. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2024 Versus 2033
5.3. Market Segmentation
5.3.1. Adenocarcinoma
5.3.2. Squamous cell carcinoma
5.3.3. Large cell carcinoma
5.3.4. Other types
6. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2024 Versus 2033
6.3. Market Segmentation
6.3.1. Chemotherapy
6.3.2. Immunotherapy
6.3.3. Targeted therapy
6.3.4. Other treatment types
7. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2024 Versus 2033
7.3. Market Segmentation
7.3.1. Male
7.3.2. Female
8. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
8.1. Market Overview
8.2. Growth & Revenue Analysis: 2024 Versus 2033
8.3. Market Segmentation
8.3.1. Hospitals
8.3.2. Specialty clinics
8.3.3. Other end use
9. North America Non-Small Cell Lung Cancer Market, 2023-2033, USD (Million)
9.1. Market Overview
9.2. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
9.3. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
9.4. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
9.5. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
9.6. Non-Small Cell Lung Cancer Market: By Region, 2023-2033, USD (Million)
9.6.1. North America
9.6.1.1. U.S.
9.6.1.1.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
9.6.1.1.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
9.6.1.1.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
9.6.1.1.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
9.6.1.2. Canada
9.6.1.2.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
9.6.1.2.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
9.6.1.2.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
9.6.1.2.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
9.6.1.3. Rest of North America
9.6.1.3.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
9.6.1.3.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
9.6.1.3.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
9.6.1.3.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
10. UK and European Union Non-Small Cell Lung Cancer Market, 2023-2033, USD (Million)
10.1. Market Overview
10.2. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
10.3. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
10.4. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
10.5. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
10.6. Non-Small Cell Lung Cancer Market: By Region, 2023-2033, USD (Million)
10.6.1. UK and European Union
10.6.1.1. UK
10.6.1.1.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
10.6.1.1.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
10.6.1.1.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
10.6.1.1.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
10.6.1.2. Germany
10.6.1.2.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
10.6.1.2.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
10.6.1.2.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
10.6.1.2.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
10.6.1.3. Spain
10.6.1.3.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
10.6.1.3.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
10.6.1.3.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
10.6.1.3.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
10.6.1.4. Italy
10.6.1.4.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
10.6.1.4.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
10.6.1.4.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
10.6.1.4.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
10.6.1.5. France
10.6.1.5.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
10.6.1.5.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
10.6.1.5.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
10.6.1.5.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
10.6.1.6. Rest of Europe
10.6.1.6.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
10.6.1.6.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
10.6.1.6.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
10.6.1.6.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
11. Asia Pacific Non-Small Cell Lung Cancer Market, 2023-2033, USD (Million)
11.1. Market Overview
11.2. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
11.3. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
11.4. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
11.5. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
11.6. Non-Small Cell Lung Cancer Market: By Region, 2023-2033, USD (Million)
11.6.1. Asia Pacific
11.6.1.1. China
11.6.1.1.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
11.6.1.1.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
11.6.1.1.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
11.6.1.1.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
11.6.1.2. Japan
11.6.1.2.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
11.6.1.2.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
11.6.1.2.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
11.6.1.2.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
11.6.1.3. India
11.6.1.3.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
11.6.1.3.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
11.6.1.3.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
11.6.1.3.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
11.6.1.4. Australia
11.6.1.4.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
11.6.1.4.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
11.6.1.4.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
11.6.1.4.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
11.6.1.5. South Korea
11.6.1.5.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
11.6.1.5.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
11.6.1.5.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
11.6.1.5.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
11.6.1.6. Rest of Asia Pacific
11.6.1.6.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
11.6.1.6.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
11.6.1.6.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
11.6.1.6.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
12. Latin America Non-Small Cell Lung Cancer Market, 2023-2033, USD (Million)
12.1. Market Overview
12.2. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
12.3. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
12.4. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
12.5. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
12.6. Non-Small Cell Lung Cancer Market: By Region, 2023-2033, USD (Million)
12.6.1. Latin America
12.6.1.1. Brazil
12.6.1.1.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
12.6.1.1.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
12.6.1.1.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
12.6.1.1.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
12.6.1.2. Mexico
12.6.1.2.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
12.6.1.2.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
12.6.1.2.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
12.6.1.2.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
12.6.1.3. Rest of Latin America
12.6.1.3.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
12.6.1.3.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
12.6.1.3.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
12.6.1.3.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
13. Middle East and Africa Non-Small Cell Lung Cancer Market, 2023-2033, USD (Million)
13.1. Market Overview
13.2. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
13.3. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
13.4. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
13.5. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
13.6. Non-Small Cell Lung Cancer Market: By Region, 2023-2033, USD (Million)
13.6.1. Middle East and Africa
13.6.1.1. GCC
13.6.1.1.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
13.6.1.1.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
13.6.1.1.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
13.6.1.1.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
13.6.1.2. Africa
13.6.1.2.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
13.6.1.2.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
13.6.1.2.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
13.6.1.2.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
13.6.1.3. Rest of Middle East and Africa
13.6.1.3.1. Non-Small Cell Lung Cancer Market: By Type, 2023-2033, USD (Million)
13.6.1.3.2. Non-Small Cell Lung Cancer Market: By Treatment, 2023-2033, USD (Million)
13.6.1.3.3. Non-Small Cell Lung Cancer Market: By Gender, 2023-2033, USD (Million)
13.6.1.3.4. Non-Small Cell Lung Cancer Market: By End Use, 2023-2033, USD (Million)
14. Company Profiles
14.1. Astellas Pharma (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
14.2. AstraZeneca
14.3. Eli Lilly
14.4. F. Hoffmann La Roche
14.5. Janssen Biotech
14.6. Merck & Co.
14.7. Novartis
14.8. Pfizer
14.9. Sanofi
14.10. Sun Pharmaceutical
14.11. Other Notable Players
List of Figures
FIG. 1 Global Non-Small Cell Lung Cancer Market: Market Coverage
FIG. 2 Research Methodology and Data Sources
FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
FIG. 4 Global Non-Small Cell Lung Cancer Market: Quality Assurance
FIG. 5 Global Non-Small Cell Lung Cancer Market, By Type, 2024
FIG. 6 Global Non-Small Cell Lung Cancer Market, By Treatment, 2024
FIG. 7 Global Non-Small Cell Lung Cancer Market, By Gender, 2024
FIG. 8 Global Non-Small Cell Lung Cancer Market, By End Use, 2024
FIG. 9 Global Non-Small Cell Lung Cancer Market, By Geography, 2024
FIG. 10 Market Geographical Opportunity Matrix - Global Non-Small Cell Lung Cancer Market, 2024
FIG. 11 Market Positioning of Key Non-Small Cell Lung Cancer Market Players, 2024
FIG. 12 Global Non-Small Cell Lung Cancer Market, By Type, 2024 Vs 2033, %
FIG. 13 Global Non-Small Cell Lung Cancer Market, By Treatment, 2024 Vs 2033, %
FIG. 14 Global Non-Small Cell Lung Cancer Market, By Gender, 2024 Vs 2033, %
FIG. 15 Global Non-Small Cell Lung Cancer Market, By End Use, 2024 Vs 2033, %
FIG. 16 U.S. Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 17 Canada Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 18 Rest of North America Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 19 UK Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 20 Germany Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 21 Spain Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 22 Italy Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 23 France Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 24 Rest of Europe Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 25 China Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 26 Japan Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 27 India Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 28 Australia Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 29 South Korea Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 30 Rest of Asia Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 31 Brazil Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 32 Mexico Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 33 Rest of Latin America Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 34 GCC Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 35 Africa Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
FIG. 36 Rest of Middle East and Africa Non-Small Cell Lung Cancer Market (US$ Million), 2023 - 2033
List of Tables
Table 1 Global Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 2 Global Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 3 Global Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 4 Global Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 5 North America Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 6 North America Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 7 North America Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 8 North America Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 9 U.S. Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 10 U.S. Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 11 U.S. Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 12 U.S. Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 13 Canada Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 14 Canada Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 15 Canada Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 16 Canada Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 17 Rest of North America Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 18 Rest of North America Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 19 Rest of North America Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 20 Rest of North America Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 21 UK and European Union Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 22 UK and European Union Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 23 UK and European Union Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 24 UK and European Union Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 25 UK Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 26 UK Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 27 UK Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 28 UK Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 29 Germany Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 30 Germany Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 31 Germany Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 32 Germany Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 33 Spain Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 34 Spain Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 35 Spain Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 36 Spain Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 37 Italy Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 38 Italy Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 39 Italy Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 40 Italy Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 41 France Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 42 France Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 43 France Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 44 France Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 45 Rest of Europe Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 46 Rest of Europe Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 47 Rest of Europe Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 48 Rest of Europe Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 49 Asia Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 50 Asia Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 51 Asia Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 52 Asia Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 53 China Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 54 China Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 55 China Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 56 China Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 57 Japan Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 58 Japan Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 59 Japan Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 60 Japan Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 61 India Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 62 India Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 63 India Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 64 India Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 65 Australia Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 66 Australia Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 67 Australia Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 68 Australia Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 69 South Korea Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 70 South Korea Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 71 South Korea Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 72 South Korea Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 73 Latin America Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 74 Latin America Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 75 Latin America Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 76 Latin America Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 77 Brazil Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 78 Brazil Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 79 Brazil Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 80 Brazil Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 81 Mexico Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 82 Mexico Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 83 Mexico Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 84 Mexico Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 85 Rest of Latin America Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 86 Rest of Latin America Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 87 Rest of Latin America Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 88 Rest of Latin America Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 89 Middle East and Africa Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 90 Middle East and Africa Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 91 Middle East and Africa Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 92 Middle East and Africa Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 93 GCC Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 94 GCC Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 95 GCC Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 96 GCC Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 97 Africa Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 98 Africa Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 99 Africa Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 100 Africa Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)
Table 101 Rest of Middle East and Africa Non-Small Cell Lung Cancer Market By Type, 2023-2033, USD (Million)
Table 102 Rest of Middle East and Africa Non-Small Cell Lung Cancer Market By Treatment, 2023-2033, USD (Million)
Table 103 Rest of Middle East and Africa Non-Small Cell Lung Cancer Market By Gender, 2023-2033, USD (Million)
Table 104 Rest of Middle East and Africa Non-Small Cell Lung Cancer Market By End Use, 2023-2033, USD (Million)

Companies Mentioned

  • Astellas Pharma
  • AstraZeneca
  • Eli Lilly
  • F. Hoffmann La Roche
  • Janssen Biotech
  • Merck & Co.
  • Novartis
  • Pfizer
  • Sanofi
  • Sun Pharmaceutical

Related Topics

Related Reports

Lung Cancer Therapeutics Market 2025-2033 - Product Image

Lung Cancer Therapeutics Market 2025-2033

  • Report
  • 140 Pages
  • Global
From
Docetaxel Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033 - Product Image

Docetaxel Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033

  • Report
  • 197 Pages
  • Global
From
Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032 - Product Image

Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • 630 Pages
  • Global
From
Non-small cell lung cancer (NSCLC) Patient Pool Analysis, Market Size and Market Forecast APAC - 2034 - Product Image

Non-small cell lung cancer (NSCLC) Patient Pool Analysis, Market Size and Market Forecast APAC - 2034

  • Report
  • 120 Pages
  • Asia Pacific
From
China Lung Cancer Therapeutics Market Size, Share and Trends Analysis Report by Disease Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), Therapeutic Class (Chemotherapy, Immunotherapy) 2024-2030 - Product Image

China Lung Cancer Therapeutics Market Size, Share and Trends Analysis Report by Disease Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), Therapeutic Class (Chemotherapy, Immunotherapy) 2024-2030

  • Report
  • 150 Pages
  • China
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.